Genprex, Inc.

08/20/2026

Did you know? Genprex has treated more than 100 patients with Reqorsa® Gene Therapy throughout its various past and currently ongoing clinical trials.

We believe REQORSA’s novel approach to targeting lung cancer, which comes with a strong safety profile, is paving new ground in the fight against lung cancer. As seen in five different Phase 1 clinical trials, REQORSA is generally well-tolerated with minimal mild side effects, and symptoms decrease with repeat cycles. REQORSA has also been shown to have no Dose Limiting Toxicities in each clinical study it has been tested thus far.

While other cancer treatments can cause harsh side effects, harm healthy tissues and organs and have other long-term effects, we believe in REQORSA’s high degree of patient safety and tolerability.

We look forward to continuing to treat as many patients as possible who have unmet medical need.

08/18/2026

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy: https://ow.ly/itqj50ZATeA

08/03/2026

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies: https://ow.ly/cor250ZvMn9

06/22/2026

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer: https://ow.ly/XFjR50ZfcY8

06/17/2026

Genprex to Participate at BIO International Convention 2026: https://ow.ly/rqQL50ZcIk8

06/02/2026

A few members from the Genprex team attended this week where our collaborators' abstract was published detailing positive clinical data from studies of predictive biomarkers in patients receiving Reqorsa® for the treatment of .

05/26/2026

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting: https://ow.ly/Gh3f50Z4bQq

05/15/2026

Our research collaborators presented positive preclinical data on our diabetes gene therapy at the 2026 ASGCT Annual Meeting. The poster, titled, "Pancreatic Delivery of AAV-Pdx1/MafA Reverses Hyperglycemia in a Preclinical Model of Type 2 Diabetes" can be reviewed in detail by clicking here: https://ow.ly/k82A50Z0ee5

05/14/2026

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting: https://ow.ly/GOrs50YZtGm

05/13/2026

Genprex was featured in Cure's Member Spotlight series, where they highlight the groundbreaking work of the companies and individuals in Cure’s community. Check out the Q&A with Genprex's President and CEO here: https://ow.ly/WjmF50YZ0Nt

A Q&A with CEO of Genprex on the intravenous gene therapy platform behind Reqorsa, how the company is advancing pipelines in both lung cancer and diabetes, and what it still needs to prove.